Midazolam Pediatric Dose — Sedation & Anxiolysis
Midazolam is a short-acting benzodiazepine that potentiates GABA-mediated inhibition in the CNS, producing dose-dependent anxiolysis, sedation, and anterograde amnesia. It is one of the most widely used agents in pediatric procedural sedation, preoperative anxiolysis, and acute agitation management. Its multiple available routes (IV, oral, and intranasal) make it particularly versatile across inpatient, emergency, and outpatient pediatric settings.
Pediatric Dosing
| Route | Dose | Frequency | Maximum Single Dose |
|---|---|---|---|
| Intravenous (IV) | 0.1 mg/kg/dose | Every 1 hour PRN | 5 mg/dose |
| Oral (PO) | 0.25–0.5 mg/kg/dose | Single or PRN | 20 mg/dose |
| Intranasal (IN) | 0.2–0.3 mg/kg/dose | Single or PRN | 10 mg/dose |
Worked example — 20 kg child:
- IV: 20 × 0.1 mg/kg = 2 mg IV (well within 5 mg max)
- PO: 20 × 0.25–0.5 mg/kg = 5–10 mg PO (within 20 mg max)
- Intranasal: 20 × 0.2–0.3 mg/kg = 4–6 mg IN (within 10 mg max)
Indications and Clinical Context
Midazolam is indicated for procedural sedation, preoperative anxiolysis, and management of acute agitation or anxiety in pediatric patients. In the emergency and intensive care setting, IV midazolam is a first-line option for rapid sedation and is incorporated into PALS-aligned protocols for status epilepticus and procedural preparation. The oral formulation is commonly used 20–30 minutes before procedures or imaging when IV access is not yet established, while the intranasal route provides a needle-free alternative for acutely anxious or uncooperative children.
Route selection is typically guided by the clinical urgency, patient cooperation, and available access. All three routes have well-established efficacy in the pediatric literature and are recognized in standard institutional sedation guidelines.
Administration and Monitoring
For IV administration, inject slowly over 2–3 minutes and titrate to effect; rapid bolus increases the risk of apnea and hypotension. The oral formulation may be mixed with a small volume of flavored liquid to improve palatability and should be administered approximately 20–30 minutes before the procedure. For intranasal delivery, use a concentrated formulation (typically 5 mg/mL) via mucosal atomization device (MAD); divide the dose equally between nostrils if the volume exceeds 0.5 mL per nostril to optimize mucosal absorption.
- Monitoring: Continuous pulse oximetry, respiratory rate, and level of consciousness for all routes; capnography recommended for deeper procedural sedation.
- Adverse effects: Respiratory depression, apnea, hypotension, paradoxical agitation (particularly in young children).
- Reversal: Flumazenil is available for benzodiazepine reversal; resuscitation equipment should be immediately accessible.
- Contraindications: Known hypersensitivity to benzodiazepines; use with caution in patients with compromised airway reflexes or hemodynamic instability.
- Consult institutional protocol for weight-based dose adjustments in neonates or patients with hepatic impairment.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.